What is Pylocura®️?

Pylocura®️ is in dietetic food for special medical purposes (balanced diet) for diet management in Helicobacter pylori infection.

Pylocura® contains patented inactivated lactic acid bacteria Pylopass® ️ (DSM17648), which physically bind and eliminate the harmful Helicobacter pylori bacteria.

By reducing the bacterial density, a renewed settlement of the Helicobacter pylori bacteria on the gastric mucosa is greatly reduced.

consumption recommendation

Take two capsules a day unchewed with plenty of liquid (e.g. a glass of water) immediately before or during a solid meal.

A minimum of 3 months' use is recommended


Ingredients: Inactivated strain Lactobacillus reuteri DSM17648

Filler: rice flour

Capsule shell: hydroxypropylmethyl cellulose

Free of gluten, lactose and fructose.

Suitable for diabetics.

important instructions

Store at room temperature.

Keep out of reach of children.

Use a balanced diet only under medical supervision..

The pathogenic bacterium Helicobacter pylori causes problems in the stomach and can lead to gastritis and ulcers. We have identified a probiotic Lactobacillus strain in our microbial strain collection that is highly specific against Helicobacter pylori. The product is available under the brand name Pylopass®.



Helicobacter pylori is a gram-negative rod bacterium.

An infection with Helicobacter pylori is the main cause of the development of gastric and duodenal ulcers, which was wrongly explained with "stomach acidity" before the discovery of the microbe.

Around 50% of all people worldwide are infected with Helicobacter pylori, whereby this microbe colonization can trigger gastritis, which is the case with about 10% of all people with "Helicobacter pyrolis present in the stomach".

Pathways of infection are bacterially infected objects, water, food, etc., whereby protection is only possible through appropriate hygiene.

In China, 60% of all adults and approximately 30% of all children are said to be infected with Helicobacter pylori. The longer an infection persists, the more likely it is that an appropriate gastric disease will break out.

Typical symptoms and problems of Helicobacter pylori infection

General signs of Helicobacter pylori infection are bloating, belching, nausea, and burning pain in the upper abdomen.

A stomach ulcer can be recognized by nighttime pain and increased discomfort after eating.

The problem is the permanent colonization of the gastric mucosa with Helicobacter pylori through overcoming the immune system. The bacteria can survive there for decades and have a harmful effect on health.

A duodenal ulcer can follow, as well as stomach cancer. Risk factors such as smoking and alcohol consumption should be avoided.

Therapy options for combating Helicobacter pylori


Antibiotics have side effects and these effects often overshadow the benefits of such therapy. Antibiotics are therefore not recommended for children and old people to fight Helicobacter pylori.

Helicobacter pylori shows a high level of resistance to various antibiotics. This relative insensitivity to antibiotic medication increases steadily over time.


Studies with Lactobacillus reuteri preparations (non-viable microbes) have shown that the Helicobacter pylori population in the stomach can be reduced. This probiotic therapy should be considered as the preferred healing method. No side effects are caused as the probiotic consists of all-natural ingredients.

Press and studies

Our products are based on innovative research.

Significant Reduction in Helicobacter pylori Load in Humans with Non-viable Lactobacillus reuteri DSM17648: A Pilot Study

Caterina Holz, Andreas Busjahn, Heidrun Mehling, Stefanie Arya, Mewes Boettner, Hajar Habibi, and Christine Langcorresponding author

Lactobacillus reuteri DSM17648 was identified as a highly specific binding antagonist to H. pylori among more than 700 wild-type strains of Lactobacillus species.

The full study can be found at:


Fight Helicobacter pylori with bacteria

Prof. Dr. C Lang & Dr. C. Wood

[...] The efficient and rapid aggregation of Lactobacillus reuteri DSM17648 with and binding to H. pylori under gastric conditions is new. This ability is specific to the L. reuteri strain DSM17648. Numerous other Lactobacillus strains from the [...] collection with> 8000 wild-type strains [...] do not show this property. [...] The binding takes place within seconds.

The full study can be found at:


Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans

Heidrun Mehling1 and Andreas Busjahn

H. pylori is a gram negative, spiral-shaped human pathogen infecting an estimated 50% of the global population. The average prevalence in developed countries in those <40 years old is 20% whereas developing countries have a prevalence rate of 80%–90%

The full study can be found at:


Efficacy and safety of Lactobacillus reuteri DSMZ17648 in patients infected with Helicobacter pylori and not having absolute indications for eradication therapy

Bordin D.S., Voynovan I. N., Khomeriki S. G., Yanova O. B., Kim V.A., Bystrovskaya E.V., Shishin K.V

Helicobacter pylori (HP) is one of the most common human infections.

The full study can be found at:


Gastric microbiota and probiotics opportunities in helicobacter pylori eradication in children

Elena A Kornienko, Natalia I. Parolova, Sergey V. Ivanov, Dmitry S Polev, Pavel A, Zykin, Yulia D. Kondratenko, Mikhail M. Zakharchenko,

Probiotics can have a direct antagonistic effect on H. pylori due to their metabolites.

The amount of lactic acid secreted by Lactobacillus, Bifidobacterium and Pediococcus (50-156mmol)

correlates with the intensity of the inhibitory effect on H. pylori.

The full study can be found at: